Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
ESMO 2025
If approved, how will you choose between Disitamab Vedotin/Toripalimib (DV+T) and EV+Pembro (EV-303), in those patients with HER2+ mUC?
Related Questions
In light of the pending overall survival data and reported declines in quality of life associated with the PSMAddition trial, how do you envision incorporating Pluvicto into the management of mHSPC?
Do the results of IMvigor011 influence you to utilize ctDNA to guide all adjuvant IO in MIBC?
What are your top takeaways in GU Cancers from ESMO 2025?
Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?
In which patients are referring for focal gland therapy for localized prostate cancer?
In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
What would be your recommended regimen for an AYA patient with relapsed mediastinal pure seminoma, with relapse 20 months after completion of BEP?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
What is your preferred treatment for a patient with refractory metastatic upper tract urothelial carcinoma previously treated with adjuvant gemcitabine/cisplatin, enfortumab vedotin + pembrolizumab, docetaxel and sacituzumab govitecan?
